Article info

PDF
Original article
Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol

Authors

  1. Correspondence to Professor Francesco Danilo Tiziano, Institute of Genomic Medicine, Catholic University, Roma 00168, Italy; francescodanilo.tiziano{at}unicatt.it
View Full Text

Citation

Tiziano FD, Lomastro R, Abiusi E, et al
Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol

Publication history

  • Received May 11, 2018
  • Revised November 10, 2018
  • Accepted November 30, 2018
  • First published December 28, 2018.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.